EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Innovation trajectory of Software as a Medical Device: Evidence from the US FDA-approved products

Jiakan Yu iD, Jiajie Zhang, Shuto Miyashita, Shintaro Sengoku iD

DIGITAL HEALTH · 2026-02 · 12

DOI: 10.1177/20552076261464265 ↗

Kurz gefasst

Fachartikel in der Zeitschrift DIGITAL HEALTH, online erschienen am 29.06.2026. Verfasst von Jiakan Yu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Innovation Science, School of Environment and Society, Institute of Science Tokyo, Tokyo, Japan. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Science and Technology Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Digital health innovation is reshaping healthcare, with Software as a Medical Device (SaMD) as a critical frontier. However, little is known about how enterprises evolve portfolios within this regulated market.

Objectives

This study uses enterprise-level SaMD product portfolio data to characterize innovation trajectories in SaMD development and assess heterogeneity in these trajectories across enterprise characteristics.

Methods

We identify 578 FDA-approved products from 289 enterprises (2012–2022) using the OpenFDA database. A multi-state model tracked innovation dynamics across 4 states: (1) one initial approval, (2) multiple approvals in identical area, (3) expansion into 2 areas, and (4) diversification into 3 or more areas. We apply Kaplan–Meier survival analysis with log-rank tests, Competing-risk cumulative incidence analysis, and Cox proportional hazards regression to examine how enterprise size and industry classification influenced portfolio expansion, with right-censoring at the observation end date.

Results

The analysis reveals stagnating innovation trajectories. 67% (n=193) of enterprises made only a single FDA submission. Kaplan-Meier estimation yielded a median time to first portfolio expansion of 8.41 years over a 10-year observation window, with large enterprises transitioning significantly faster than micro enterprises ( p

Schlagwörter

Stichwörter der Autor:innen

digital healthdigital innovationinnovation trajectoryregulated marketsoftware as a medical device

Autor:innen und Institutionen

  • Department of Innovation Science, School of Environment and Society, Institute of Science Tokyo, Tokyo, Japan.
  • Graduate School of Interdisciplinary Information Studies, The University of Tokyo, Tokyo, Japan.

ORCID-Profile: Jiakan Yu, Shintaro Sengoku

Förderung

  • Japan Science and Technology Agency

Zitieren

APA

Yu, J., Zhang, J., Miyashita, S., & Sengoku, S. (2026). Innovation trajectory of Software as a Medical Device: Evidence from the US FDA-approved products. DIGITAL HEALTH, 12. https://doi.org/10.1177/20552076261464265

Vancouver

Yu J, Zhang J, Miyashita S, Sengoku S. Innovation trajectory of Software as a Medical Device: Evidence from the US FDA-approved products. DIGITAL HEALTH. 2026;12. doi:10.1177/20552076261464265

BibTeX
@article{Yu2026,
  author = {Yu, Jiakan and Zhang, Jiajie and Miyashita, Shuto and Sengoku, Shintaro},
  title = {Innovation trajectory of Software as a Medical Device: Evidence from the US FDA-approved products},
  journal = {DIGITAL HEALTH},
  year = {2026},
  volume = {12},
  doi = {10.1177/20552076261464265}
}
Kostenlos starten →